Cargando…

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

BACKGROUND: Treatment adherence is one of the key factors for achieving optimal clinical outcomes. In order to assess costs related to adherence to, and persistence and compliance with, disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS), a narrative review of the literature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lizán, Luis, Comellas, Marta, Paz, Silvia, Poveda, José Luis, Meletiche, Dennis M, Polanco, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262214/ https://www.ncbi.nlm.nih.gov/pubmed/25525341 http://dx.doi.org/10.2147/PPA.S67253

Ejemplares similares

Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
por: Garcia-Dominguez, José Manuel, et al.
Publicado: (2016)

Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
por: Kozma, Chris M., et al.
Publicado: (2014)

Additional Value of Patient-Reported Symptom Monitoring in Cancer Care: A Systematic Review of the Literature
por: Lizán, Luís, et al.
Publicado: (2021)

Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis
por: Kozma, Chris M, et al.
Publicado: (2013)

Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature
por: Torre-Alonso, Juan Carlos, et al.
Publicado: (2018)

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature
por: Belinchón, I, et al.
Publicado: (2016)

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
por: Goldberg, Lawrence, et al.
Publicado: (2009)

The Impact of Patient Support Programs in Europe: A Systematic Literature Review
por: Sacristán, José Antonio, et al.
Publicado: (2022)

Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life
por: Gracia, Fernando, et al.
Publicado: (2018)

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
por: Blade, Joan, et al.
Publicado: (2018)

Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting
por: Escudero-Vilaplana, Vicente, et al.
Publicado: (2020)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

The Perspective of Patients and Health Professionals on the Prioritization of Assisted Reproductive Techniques. The PRIOFER Study
por: Lizán Tudela, César, et al.
Publicado: (2023)

Multiple Sclerosis and Other Demyelinating Diseases
por: Soldan, Samantha S., et al.
Publicado: (2008)

Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
por: Montoya, Alonso, et al.
Publicado: (2011)

El visado de inspección de medicamentos en España: situación actual desde la perspectiva de los profesionales sanitarios a partir de la introducción de su modalidad electrónica()
por: Orozco, Domingo, et al.
Publicado: (2013)

Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology
por: Sacristán, José A., et al.
Publicado: (2016)

Patient Decision Aid (PDA) for Patients with Rheumatoid Arthritis Reduces Decisional Conflict and Improves Readiness for Treatment Decision Making
por: Pablos, José Luis, et al.
Publicado: (2019)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis
por: Martinez-Martín, Pablo, et al.
Publicado: (2015)

The cost of multiple sclerosis in Norway
por: Svendsen, B., et al.
Publicado: (2010)

Adherence to Therapy in Patients with Multiple Sclerosis—Review
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2022)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
por: Díaz-Torné, Cesar, et al.
Publicado: (2020)

Comprehensive population-based determination of pediatric multiple sclerosis health care costs
por: Wright, Melissa A., et al.
Publicado: (2016)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Therapeutic adherence and coping strategies in patients with multiple sclerosis: An observational study
por: Corallo, Francesco, et al.
Publicado: (2019)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Willingness to pay and conjoint analysis to determine women's preferences for ovarian stimulating hormones in the treatment of infertility in Spain
por: Palumbo, A., et al.
Publicado: (2011)

The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis
por: Tarrants, M., et al.
Publicado: (2011)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain
por: Soria, Cristina, et al.
Publicado: (2023)

Adherence to Mediterranean Diet Is Associated with Multiple Sclerosis Severity
por: Guglielmetti, Monica, et al.
Publicado: (2023)

Burden and cost of multiple sclerosis in Brazil
por: Kobelt, Gisela, et al.
Publicado: (2019)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
por: Evans, Charity, et al.
Publicado: (2021)

Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature
por: Yamamoto, David, et al.
Publicado: (2012)

Cuidado Con Las Comparaciones Indirectas: A Proposito De Los Nuevos Anticoagulantes Orales
por: Lizán, Luis
Publicado: (2013)

MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases
por: Mechelli, Rosella, et al.
Publicado: (2021)

Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases
por: Kušnierová, Pavlína, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bos5ic79f9gop94uopqtmm9je4